Diclofenac methyl ester

CAS No. 15307-78-5

Diclofenac methyl ester ( —— )

Catalog No. M28130 CAS No. 15307-78-5

Diclofenac methyl ester is a hydrophobic prodrug form of diclofenac which is a non-steroidal anti-inflammatory drug (NSAID).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 In Stock
10MG 63 In Stock
25MG 103 In Stock
50MG 150 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Diclofenac methyl ester
  • Note
    Research use only, not for human use.
  • Brief Description
    Diclofenac methyl ester is a hydrophobic prodrug form of diclofenac which is a non-steroidal anti-inflammatory drug (NSAID).
  • Description
    Diclofenac methyl ester is a hydrophobic prodrug form of diclofenac which is a non-steroidal anti-inflammatory drug (NSAID). Diclofenac methyl ester is more soluble than diclofenac acid in isopropylmyristate but with higher toxicity.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    luciferase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    15307-78-5
  • Formula Weight
    310.2
  • Molecular Formula
    C15H13Cl2NO2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Haneen Amawi, et al. The use of zebrafish model in prostate cancer therapeutic development and discovery. Cancer Chemother Pharmacol. 2021 Mar;87(3):311-325.
molnova catalog
related products
  • Progabide

    Progabide is an agonist of the gamma-aminobutyric acid receptor.

  • EcDsbB-IN-9

    EcDsbB-IN-9 is a specific EcDsbB inhibitor, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria.

  • 5alpha-Hydroxycostic...

    5alpha-Hydroxycostic acid possesses anti-angiogenic ability by interfering the VEGF- and Ang2-related pathways, and it may be a good drug candidate.